Search company, investor...

KuDOS Pharmaceuticals

Stage

Acquired | Acquired

Total Raised

$43.7M

Valuation

$0000 

About KuDOS Pharmaceuticals

KuDOS is involved in the discovery and development of small molecule drugs based upon the science of DNA damage sensing, signalling and repair to address unmet medical needs in cancer treatment.

Headquarters Location

410 Cambridge Science Park

Cambridge, England, CB4 0PE,

United Kingdom

Missing: KuDOS Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: KuDOS Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing KuDOS Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

KuDOS Pharmaceuticals is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

KuDOS Pharmaceuticals Patents

KuDOS Pharmaceuticals has filed 1 patent.

The 3 most popular patent topics include:

  • Proteins
  • Antineoplastic drugs
  • Block ciphers
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/11/2019

11/2/2021

Block ciphers, Antineoplastic drugs, Simple aromatic rings, Proteins, Transcription factors

Grant

Application Date

9/11/2019

Grant Date

11/2/2021

Title

Related Topics

Block ciphers, Antineoplastic drugs, Simple aromatic rings, Proteins, Transcription factors

Status

Grant

Latest KuDOS Pharmaceuticals News

Merck halts Phase 3 Lynparza for futility

Jul 19, 2022

July 18, 2022 Merck (NYSE:MRK) has announced that it will stop the Phase 3 LYNK-003 trial focused on Lynparza (olaparib) with or without bevacizumab for patients with unresectable or metastatic colorectal cancer. Two experimental arms in the trial, one focused on Lynparza as monotherapy or in combination with the immunotherapy drug bevacizumab, will be suspended. The primary endpoint of the trial was progression-free survival. The study focused on patients without progression after first-line therapy. Merck made the decision after receiving feedback from an independent Data Monitoring Committee (DMC) following review from an interim analysis. The PARP inhibitor Lynparza was first developed by KuDOS Pharmaceuticals and the University of Pennsylvania. AstraZeneca acquired KuDOS Pharmaceuticals in 2005. In 2021, the drug jointly earned AstraZeneca and Merck $3.7 billion. The two companies continue to develop Lynparza for a variety of oncology indications, including metastatic breast, prostate, ovarian and pancreatic cancer. The drug first won FDA approval for maintenance treatment of ovarian cancer in 2017. MRK shares dipped 2.76% to $92.34 while AZN shares were up 0.63% to £11,200.00.

KuDOS Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is KuDOS Pharmaceuticals's headquarters?

    KuDOS Pharmaceuticals's headquarters is located at 410 Cambridge Science Park, Cambridge.

  • What is KuDOS Pharmaceuticals's latest funding round?

    KuDOS Pharmaceuticals's latest funding round is Acquired.

  • How much did KuDOS Pharmaceuticals raise?

    KuDOS Pharmaceuticals raised a total of $43.7M.

  • Who are the investors of KuDOS Pharmaceuticals?

    Investors of KuDOS Pharmaceuticals include AstraZeneca, Novartis Venture Funds, Advent Venture Partners, EuclidSR Partners, Schroders and 7 more.

  • Who are KuDOS Pharmaceuticals's competitors?

    Competitors of KuDOS Pharmaceuticals include Aquinox Pharmaceuticals, Histogenics, Akebia Therapeutics, Forte Biosciences, Relypsa and 13 more.

Compare KuDOS Pharmaceuticals to Competitors

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

S
SBIO Pte

SBIO is focused on the discovery and development of small molecule oncology drugs.

N
NexGenix Pharmaceuticals Holdings

NexGenix Pharmaceuticals is developing drugs for cancer, neurodegenerative diseases, and neurofibromatosis.

N
Neotropix

Neotropix 1 is a virotherapy company, dedicated to the development and commercialization of virus-based therapies for the treatment of cancer and other diseases. Per Neotropix, virotherapy holds great promise for cancer patients because it may be more efficacious and less toxic than conventional radiation and chemotherapy.

P
Prolexys Pharmaceuticals

Prolexys Pharmaceuticals is a developer of cancer and cardiovascular small molecule drugs.

I
Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.